Cargando…
Impact of baseline patient characteristics on dupilumab efficacy in type 2 asthma
Dupilumab treatment versus placebo improved exacerbation rate and lung function outcomes in patients with uncontrolled moderate-to-severe asthma and high type 2 biomarkers at baseline, regardless of baseline characteristics in the phase 3 QUEST study https://bit.ly/3yR7MlD
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
European Respiratory Society
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8522685/ https://www.ncbi.nlm.nih.gov/pubmed/34326187 http://dx.doi.org/10.1183/13993003.04605-2020 |
| _version_ | 1784585137550262272 |
|---|---|
| author | Busse, William W. Paggiaro, Pierluigi Muñoz, Xavier Casale, Thomas B. Castro, Mario Canonica, G. Walter Douglass, Jo A. Tohda, Yuji Daizadeh, Nadia Ortiz, Benjamin Pandit-Abid, Nami |
| author_facet | Busse, William W. Paggiaro, Pierluigi Muñoz, Xavier Casale, Thomas B. Castro, Mario Canonica, G. Walter Douglass, Jo A. Tohda, Yuji Daizadeh, Nadia Ortiz, Benjamin Pandit-Abid, Nami |
| author_sort | Busse, William W. |
| collection | PubMed |
| description | Dupilumab treatment versus placebo improved exacerbation rate and lung function outcomes in patients with uncontrolled moderate-to-severe asthma and high type 2 biomarkers at baseline, regardless of baseline characteristics in the phase 3 QUEST study https://bit.ly/3yR7MlD |
| format | Online Article Text |
| id | pubmed-8522685 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | European Respiratory Society |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-85226852021-10-19 Impact of baseline patient characteristics on dupilumab efficacy in type 2 asthma Busse, William W. Paggiaro, Pierluigi Muñoz, Xavier Casale, Thomas B. Castro, Mario Canonica, G. Walter Douglass, Jo A. Tohda, Yuji Daizadeh, Nadia Ortiz, Benjamin Pandit-Abid, Nami Eur Respir J Agora Dupilumab treatment versus placebo improved exacerbation rate and lung function outcomes in patients with uncontrolled moderate-to-severe asthma and high type 2 biomarkers at baseline, regardless of baseline characteristics in the phase 3 QUEST study https://bit.ly/3yR7MlD European Respiratory Society 2021-10-07 /pmc/articles/PMC8522685/ /pubmed/34326187 http://dx.doi.org/10.1183/13993003.04605-2020 Text en Copyright ©The authors 2021. https://creativecommons.org/licenses/by-nc/4.0/This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org (mailto:permissions@ersnet.org) |
| spellingShingle | Agora Busse, William W. Paggiaro, Pierluigi Muñoz, Xavier Casale, Thomas B. Castro, Mario Canonica, G. Walter Douglass, Jo A. Tohda, Yuji Daizadeh, Nadia Ortiz, Benjamin Pandit-Abid, Nami Impact of baseline patient characteristics on dupilumab efficacy in type 2 asthma |
| title | Impact of baseline patient characteristics on dupilumab efficacy in type 2 asthma |
| title_full | Impact of baseline patient characteristics on dupilumab efficacy in type 2 asthma |
| title_fullStr | Impact of baseline patient characteristics on dupilumab efficacy in type 2 asthma |
| title_full_unstemmed | Impact of baseline patient characteristics on dupilumab efficacy in type 2 asthma |
| title_short | Impact of baseline patient characteristics on dupilumab efficacy in type 2 asthma |
| title_sort | impact of baseline patient characteristics on dupilumab efficacy in type 2 asthma |
| topic | Agora |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8522685/ https://www.ncbi.nlm.nih.gov/pubmed/34326187 http://dx.doi.org/10.1183/13993003.04605-2020 |
| work_keys_str_mv | AT bussewilliamw impactofbaselinepatientcharacteristicsondupilumabefficacyintype2asthma AT paggiaropierluigi impactofbaselinepatientcharacteristicsondupilumabefficacyintype2asthma AT munozxavier impactofbaselinepatientcharacteristicsondupilumabefficacyintype2asthma AT casalethomasb impactofbaselinepatientcharacteristicsondupilumabefficacyintype2asthma AT castromario impactofbaselinepatientcharacteristicsondupilumabefficacyintype2asthma AT canonicagwalter impactofbaselinepatientcharacteristicsondupilumabefficacyintype2asthma AT douglassjoa impactofbaselinepatientcharacteristicsondupilumabefficacyintype2asthma AT tohdayuji impactofbaselinepatientcharacteristicsondupilumabefficacyintype2asthma AT daizadehnadia impactofbaselinepatientcharacteristicsondupilumabefficacyintype2asthma AT ortizbenjamin impactofbaselinepatientcharacteristicsondupilumabefficacyintype2asthma AT panditabidnami impactofbaselinepatientcharacteristicsondupilumabefficacyintype2asthma |